{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:43:04Z","timestamp":1768891384182,"version":"3.49.0"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1097\/cmr.0000000000000222","type":"journal-article","created":{"date-parts":[[2015,12,25]],"date-time":"2015-12-25T13:01:29Z","timestamp":1451048489000},"page":"93-99","source":"Crossref","is-referenced-by-count":52,"title":["Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas"],"prefix":"10.1097","volume":"26","author":[{"given":"Vinicius","family":"de Lima Vazquez","sequence":"first","affiliation":[]},{"given":"Anna L.","family":"Vicente","sequence":"additional","affiliation":[]},{"given":"Adriana","family":"Carloni","sequence":"additional","affiliation":[]},{"given":"Gustavo","family":"Berardinelli","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Soares","sequence":"additional","affiliation":[]},{"given":"Cristovam","family":"Scapulatempo","sequence":"additional","affiliation":[]},{"given":"Olga","family":"Martinho","sequence":"additional","affiliation":[]},{"given":"Rui M.","family":"Reis","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R2-1-20210129","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/j.1365-2133.2003.05554.x","article-title":"Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer).","volume":"149","author":"Katalinic","year":"2003","journal-title":"Br J Dermatol"},{"key":"R3-1-20210129","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archdermatol.2008.609","article-title":"Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005.","volume":"145","author":"Bradford","year":"2009","journal-title":"Arch Dermatol"},{"key":"R4-1-20210129","first-page":"705","article-title":"The histogenesis and biologic behavior of primary human malignant melanomas of the skin.","volume":"29","author":"Clark","year":"1969","journal-title":"Cancer Res"},{"key":"R5-1-20210129","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/1097-0142(197312)32:6<1446::AID-CNCR2820320623>3.0.CO;2-8","article-title":". The classification of malignant melanoma and its histologic reporting.","volume":"32","author":"McGovern","year":"1973","journal-title":"Cancer"},{"key":"R6-1-20210129","first-page":"65","article-title":"Melanoma in black South Africans.","volume":"180","author":"Hudson","year":"1995","journal-title":"J Am Coll Surg"},{"key":"R7-1-20210129","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5070\/D33K77P755","article-title":"Malignant melanoma in African-Americans.","volume":"15","author":"Kabigting","year":"2009","journal-title":"Dermatol Online J"},{"key":"R8-1-20210129","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1001\/jamadermatol.2013.5941","article-title":"Acral melanoma: a unique disease in Asia.","volume":"149","author":"Chang","year":"2013","journal-title":"JAMA Dermatol"},{"key":"R9-1-20210129","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1590\/abd1806-4841.20131855","article-title":"Epidemiological aspects of melanoma at a university hospital dermatology center over a period of 20 years.","volume":"88","author":"Brandao","year":"2013","journal-title":"An Bras Dermatol"},{"key":"R10-1-20210129","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1590\/abd1806-4841.20132036","article-title":"Epidemiological and histopathological profile of cutaneous melanoma at a center in northeastern Brazil from 2000 to 2010.","volume":"88","author":"Vilanova","year":"2013","journal-title":"An Bras Dermatol"},{"key":"R12-1-20210129","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":". Distinct sets of genetic alterations in melanoma.","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med"},{"key":"R13-1-20210129","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/107327481302000404","article-title":"Melanoma mutagenesis and aberrant cell signaling.","volume":"20","author":"Bello","year":"2013","journal-title":"Cancer Control"},{"key":"R14-1-20210129","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nature05661","article-title":"Melanoma biology and new targeted therapy.","volume":"445","author":"Gray-Schopfer","year":"2007","journal-title":"Nature"},{"key":"R15-1-20210129","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":". Mutations of the BRAF gene in human cancer.","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"R16-1-20210129","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S1535-6108(02)00089-2","article-title":"A genome-based strategy uncovers frequent BRAF mutations in melanoma.","volume":"2","author":"Pollock","year":"2002","journal-title":"Cancer Cell"},{"key":"R17-1-20210129","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.soc.2010.09.003","article-title":"Targeted therapy for melanoma: a primer.","volume":"20","author":"Davies","year":"2011","journal-title":"Surg Oncol Clin N Am"},{"key":"R18-1-20210129","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1158\/1078-0432.CCR-05-2447","article-title":"Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.","volume":"12","author":"Saldanha","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R19-1-20210129","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma.","volume":"24","author":"Curtin","year":"2006","journal-title":"J Clin Oncol"},{"key":"R20-1-20210129","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","article-title":". Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.","volume":"31","author":"Hodi","year":"2013","journal-title":"J Clin Oncol"},{"key":"R21-1-20210129","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s003359900783","article-title":"Genomic structure of the human KDRflk-1 gene.","volume":"9","author":"Yin","year":"1998","journal-title":"Mamm Genome"},{"key":"R22-1-20210129","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1215\/15228517-2007-009","article-title":"Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme.","volume":"9","author":"Holtkamp","year":"2007","journal-title":"Neuro Oncol"},{"key":"R23-1-20210129","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":". Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"R24-1-20210129","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/1078-0432.CCR-11-1987","article-title":"Sunitinib therapy for melanoma patients with KIT mutations.","volume":"18","author":"Minor","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R25-1-20210129","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/gcc.21922","article-title":"Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis.","volume":"51","author":"Johansson","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"R26-1-20210129","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1230062","article-title":". TERT promoter mutations in familial and sporadic melanoma.","volume":"339","author":"Horn","year":"2013","journal-title":"Science"},{"key":"R27-1-20210129","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1126\/science.1229259","article-title":"Highly recurrent TERT promoter mutations in human melanoma.","volume":"339","author":"Huang","year":"2013","journal-title":"Science"},{"key":"R28-1-20210129","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/ncomms3185","article-title":". Frequency of TERT promoter mutations in human cancers.","volume":"4","author":"Vinagre","year":"2013","journal-title":"Nat Commun"},{"key":"R29-1-20210129","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.gde.2013.11.005","article-title":"TERT promoter mutations in cancer development.","volume":"24","author":"Heidenreich","year":"2014","journal-title":"Curr Opin Genet Dev"},{"key":"R30-1-20210129","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/cup.12323","article-title":"TERT promoter mutation is uncommon in acral lentiginous melanoma.","volume":"41","author":"Liau","year":"2014","journal-title":"J Cutan Pathol"},{"key":"R31-1-20210129","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.3892\/or.2014.3338","article-title":". KRAS and BRAF mutations and MSI status in precursor lesions of colorectal cancer detected by colonoscopy.","volume":"32","author":"Yamane","year":"2014","journal-title":"Oncol Rep"},{"key":"R32-1-20210129","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2559.2009.03323.x","article-title":"Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs.","volume":"55","author":"Martinho","year":"2009","journal-title":"Histopathology"},{"key":"R33-1-20210129","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/ejhg.2014.195","article-title":". Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs).","volume":"23","author":"Campanella","year":"2015","journal-title":"Eur J Hum Genet"},{"key":"R34-1-20210129","first-page":"399","article-title":". Molecular alterations of KIT oncogene in gliomas.","volume":"29","author":"Gomes","year":"2007","journal-title":"Cell Oncol"},{"key":"R35-1-20210129","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/sj.bjc.6605225","article-title":". Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas.","volume":"101","author":"Martinho","year":"2009","journal-title":"Br J Cancer"},{"key":"R36-1-20210129","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1593\/tlo.12400","article-title":". In vitro and in vivo analysis of RTK inhibitor efficacy and identification of its novel targets in glioblastomas.","volume":"6","author":"Martinho","year":"2013","journal-title":"Transl Oncol"},{"key":"R37-1-20210129","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/sj.bjc.6605225","article-title":". Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas.","volume":"101","author":"Martinho","year":"2009","journal-title":"Br J Cancer"},{"key":"R38-1-20210129","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/bjd.13069","article-title":". Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma.","volume":"171","author":"Pozzobon","year":"2014","journal-title":"Br J Dermatol"},{"key":"R39-1-20210129","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.1158\/1078-0432.CCR-13-1266","article-title":". Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.","volume":"19","author":"Dai","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R40-1-20210129","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/DAD.0b013e318279566a","article-title":". C-kit expression of melanocytic neoplasm and association with clinicopathological parameters and anatomic locations in Chinese people.","volume":"35","author":"Lin","year":"2013","journal-title":"Am J Dermatopathol"},{"key":"R41-1-20210129","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jdermsci.2013.07.013","article-title":". KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.","volume":"72","author":"Zebary","year":"2013","journal-title":"J Dermatol Sci"},{"key":"R42-1-20210129","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/exd.12080","article-title":"Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma.","volume":"22","author":"Puig-Butille","year":"2013","journal-title":"Exp Dermatol"},{"key":"R43-1-20210129","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jdermsci.2012.03.005","article-title":". Assessment of BRAF and KIT mutations in Japanese melanoma patients.","volume":"66","author":"Ashida","year":"2012","journal-title":"J Dermatol Sci"},{"key":"R44-1-20210129","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cncr.26724","article-title":". NRAS mutation status is an independent prognostic factor in metastatic melanoma.","volume":"118","author":"Jakob","year":"2012","journal-title":"Cancer"},{"key":"R45-1-20210129","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1600-0463.2011.02737.x","article-title":"KIT amplification and gene mutations in acralmucosal melanoma in Korea.","volume":"119","author":"Yun","year":"2011","journal-title":"APMIS"},{"key":"R46-1-20210129","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1158\/1078-0432.CCR-10-2346","article-title":". Large-scale analysis of KIT aberrations in Chinese patients with melanoma.","volume":"17","author":"Kong","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R47-1-20210129","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejca.2011.06.056","article-title":". Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort.","volume":"48","author":"Si","year":"2012","journal-title":"Eur J Cancer"},{"key":"R48-1-20210129","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jmoldx.2012.10.002","article-title":". Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma.","volume":"15","author":"Greaves","year":"2013","journal-title":"J Mol Diagn"},{"key":"R49-1-20210129","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/sj.bjc.6605635","article-title":". Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.","volume":"102","author":"Handolias","year":"2010","journal-title":"Br J Cancer"},{"key":"R50-1-20210129","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1755-148X.2010.00671.x","article-title":". Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure.","volume":"23","author":"Handolias","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"R51-1-20210129","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10147-010-0087-0","article-title":"Low incidence of KIT gene mutations and no PDGFRA gene mutations in primary cutaneous melanoma: an immunohistochemical and molecular genetic study of Japanese cases.","volume":"15","author":"Terada","year":"2010","journal-title":"Int J Clin Oncol"},{"key":"R52-1-20210129","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/modpathol.2009.116","article-title":". Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginousmucosal type.","volume":"22","author":"Torres-Cabala","year":"2009","journal-title":"Mod Pathol"},{"key":"R53-1-20210129","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ijc.24048","article-title":"Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas.","volume":"124","author":"Ashida","year":"2009","journal-title":"Int J Cancer"},{"key":"R54-1-20210129","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/sj.jid.5701036","article-title":"Absence of PDGFRA mutations in primary melanoma.","volume":"128","author":"Curtin","year":"2008","journal-title":"J Invest Dermatol"},{"key":"R55-1-20210129","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/CMR.0b013e3282f32517","article-title":"Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma.","volume":"18","author":"Akslen","year":"2008","journal-title":"Melanoma Res"},{"key":"R56-1-20210129","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.1158\/1078-0432.CCR-08-0575","article-title":". KIT gene mutations and copy number in melanoma subtypes.","volume":"14","author":"Beadling","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R57-1-20210129","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1111\/j.1365-2133.2007.07924.x","article-title":". Genetic and epigenetic alterations in the differential diagnosis of malignant melanoma and spitzoid lesion.","volume":"156","author":"Takata","year":"2007","journal-title":"Br J Dermatol"},{"key":"R58-1-20210129","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.0022-202X.2005.23812.x","article-title":". Constitutive activation of the mitogen-activated protein kinase signaling pathway in acral melanomas.","volume":"125","author":"Takata","year":"2005","journal-title":"J Invest Dermatol"},{"key":"R59-1-20210129","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/sj.jid.5700632","article-title":". Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma.","volume":"127","author":"Liu","year":"2007","journal-title":"J Invest Dermatol"},{"key":"R60-1-20210129","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/cncr.20861","article-title":"Absence of V599E BRAF mutations in desmoplastic melanomas.","volume":"103","author":"Davison","year":"2005","journal-title":"Cancer"},{"key":"R61-1-20210129","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.0022-202X.2005.23833.x","article-title":"Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes.","volume":"125","author":"Lang","year":"2005","journal-title":"J Invest Dermatol"},{"key":"R62-1-20210129","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.0022-202X.2004.22722.x","article-title":". BRAF point mutations in primary melanoma show different prevalences by subtype.","volume":"123","author":"Sasaki","year":"2004","journal-title":"J Invest Dermatol"},{"key":"R63-1-20210129","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/ijc.11722","article-title":"Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.","volume":"109","author":"Reifenberger","year":"2004","journal-title":"Int J Cancer"},{"key":"R64-1-20210129","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/jnci\/djg123","article-title":". Determinants of BRAF mutations in primary melanomas.","volume":"95","author":"Maldonado","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"R65-1-20210129","doi-asserted-by":"crossref","first-page":"dju246","DOI":"10.1093\/jnci\/dju246","article-title":". TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.","volume":"106","author":"Griewank","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"R66-1-20210129","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.bcp.2010.04.032","article-title":"Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.","volume":"80","author":"Woodman","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"R67-1-20210129","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.ejca.2009.05.008","article-title":". A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours.","volume":"45","author":"Baruchel","year":"2009","journal-title":"Eur J Cancer"},{"key":"R68-1-20210129","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1101\/gad.1972310","article-title":". PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas.","volume":"24","author":"Ozawa","year":"2010","journal-title":"Genes Dev"},{"key":"R69-1-20210129","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1245\/s10434-013-3373-z","article-title":"The GIST of targeted therapy for malignant melanoma.","volume":"21","author":"Bello","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"R70-1-20210129","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1158\/1078-0432.CCR-14-1630","article-title":". Phase II study of nilotinib in melanoma harboring KIT alterations following progression to prior KIT inhibition.","volume":"21","author":"Carvajal","year":"2015","journal-title":"Clin Cancer Res"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00008390-201604000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T19:33:24Z","timestamp":1653939204000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008390-201604000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000000222","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}